The effects of switching from oral to LAI antipsychotic treatment on subjective experience of schizophrenic and schizoaffective patients: Preliminary results

References

• American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorder, 4th edition. Text revision. Washington DC: American Psychiatric Publishing.
   Google Scholar
• American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders, 5th edition. Arlington, VA: American Psychiatric Publishing.
   Google Scholar
• Carpenter WT Jr, Hanlon TE, Heinrichs DW, Summerfelt AT, Kirkpatrick B, Levine J, et al. 1990. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 147:1138–1148.
   PubMed Web of Science ®Google Scholar
• Crossley NA, Constante M, McGuire P, Power P. 2010. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 196:434–439.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company, June 2012. ZypAdhera. Summary of product characteristics, EU.
   Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JBW. 2002. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, research version, patient edition (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute.
   Google Scholar
• Gerlach J. 1999. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. J Clin Psychiatry 60:20–24.
   PubMedGoogle Scholar
• Hawley CJ, Gale TM, Sivakumaran T, Hertfordshire Neuroscience Research Group. 2002. Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord 72:177–184.
   PubMed Web of Science ®Google Scholar
• Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. 2013. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol 3:200–218.
   PubMedGoogle Scholar
• Iyer S, Banks N, Roy MA, Tibbo P, Williams R, Manchanda R, et al. 2013. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives. Can J Psychiatry 58:14S–22S.
   Web of Science ®Google Scholar
• Janssen-Cilag, June 2012. Xeplion. Summary of product characteristics, EU.
   Google Scholar
• Ju PC, Chou FH, Lai TJ, Chuang PY, Lin YJ, Yang CW, et al. 2014. Long-acting injectables and risk for rehospitalization among patients with schizophrenia in the home care program in Taiwan. J Clin Psychopharmacol 34:23–29.
   PubMedGoogle Scholar
• Kane JM. 1999. Pharmacologic treatment of schizophrenia. Biol Psychiatry 46:1396–1408.
   PubMed Web of Science ®Google Scholar
• Kaplan G, Casoy J, Zummo J. 2013. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence 7:1171–1180.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–276.
   PubMed Web of Science ®Google Scholar
• Kirschner M, Theodoridou A, Fusar-Poli P, Kaiser S, Jäger M. 2013. Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Ther Adv Psychopharmacol 3:89–99.
   PubMedGoogle Scholar
• Lafeuille MH, Laliberté-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS. 2013. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry 13:221.
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. 2004. Practice guideline for the treatment of patients with schizophrenia,2nd edition. Am J Psychiatry 161: 1–56.
   PubMed Web of Science ®Google Scholar
• Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. 2005. What does the PANSS mean? Schizophr Res 79:231–238.
   PubMed Web of Science ®Google Scholar
• Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. 2012. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:2063–2071.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. 2013. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951–962.
   PubMed Web of Science ®Google Scholar
• Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. 2013. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry 13:340.
   PubMed Web of Science ®Google Scholar
• Lukasiewicz M, Gerard S, Besnard A, Falissard B, Perrin E, Sapin H, et al. 2013. Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. Int J Methods Psychiatr Res 22:46–58.
   PubMed Web of Science ®Google Scholar
• Malaspina D, Owen MJ, Heckers S, Tandon R, Bustillo J, Schultz S, et al. 2013. Schizoaffective Disorder in the DSM-5. Schizophr Res 150:21–25.
   PubMed Web of Science ®Google Scholar
• Marder SR. 2005. Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand Suppl 427:43–46.
   PubMedGoogle Scholar
• Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389.
   PubMed Web of Science ®Google Scholar
• Müller MJ, Himmerich H, Kienzle B, Szegedi A. 2003. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). J Affect Disord 77:255–260.
   PubMed Web of Science ®Google Scholar
• Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, et al. 2001. Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res 50:79–88.
   PubMed Web of Science ®Google Scholar
• Nielsen RE, Lindström E, Nielsen J, Levander S. 2012. DAI-10 is as good as DAI-30 in schizophrenia. Eur Neuropsychopharmacol 22:747–750.
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. 2010. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 176:109–113.
   PubMed Web of Science ®Google Scholar
• Rauch AS, Fleischhacker WW. 2013. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs 27:637–652.
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. 2004. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 161:473–479.
   PubMed Web of Science ®Google Scholar
• Rosa F, Schreiner A, Thomas P, Sherif T. 2012. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Clin Drug Investig 32:267–279.
   PubMed Web of Science ®Google Scholar
• Schrank B, Bird V, Tylee A, Coggins T, Rashid T, Slade M. 2013. Conceptualising and measuring the well-being of people with psychosis: systematic review and narrative synthesis. Soc Sci Med 92:9–21.
   PubMed Web of Science ®Google Scholar
• Stahl SM. 2014. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr 19:3–5.
   PubMed Web of Science ®Google Scholar
• van Os J, Kapur S. 2009. Schizophrenia. Lancet 374:635–645.
   PubMed Web of Science ®Google Scholar
• Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. 2000. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 43:135–145.
   PubMed Web of Science ®Google Scholar
• Vothknecht S, Schoevers RA, de Haan L. 2011. Subjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: a review. Aust N Z J Psychiatry 45:182–192.
   PubMed Web of Science ®Google Scholar
• Ware JE, Snow K, Kosinski M, Gamdek B. 1997. Sf-36 health survey manual and interpretation guide. The Health Institute, New England Medical Center, Boston, MA.
   Google Scholar
• Young RC, Biggs JT, Ziegler VE, Meyer DA. 1978. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435.
   PubMed Web of Science ®Google Scholar